• Regeneron is buying its headquarters in Westchester for $720 million. The move comes as the big biotech has steadily expanded its presence in the region. “This agreement will result in cost savings and also provide Regeneron with operational control of our site and future development plans,” Regeneron spokeswoman Erin Loosen told the local newspaper.
• Seattle Genetics CEO Clay Siegall had a bullish talk in store for a group of investors, telling them the company intends to add several new drugs to its portfolio in coming years with plans to add 200 new staffers by the end of this year.
• Genentech says the FDA has accepted its sBLA for Actemra (tocilizumab) for GCA, a chronic and potentially lethal autoimmune condition. The FDA also granted Priority Review Designation for Actemra for the treatment of GCA.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription